Navigation Links
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
Date:8/21/2008

Phase II Lucanix(R) study and the investigator-initiated Phase II trial.

"This is a very promising approach to cancer treatment, and results reported so far are beyond anyone's expectations. I am very excited to be a part of this confirmatory effort, and to be able to offer this unique treatment option to my patients," said Dr. Lyudmila Bazhenova, principal investigator of the STOP trial at the Rebecca and John Moore's Cancer Center of UCSD. "Traditional chemotherapy for stage IV NSCLC still yields disappointing results, and my hope is that this trial will improve the natural history of the disease." The FDA granted NovaRx Fast-Track approval for the Lucanix(R) trial in March of 2007, and Special Protocol Assessment approval in January of 2008.

According to the American Cancer Society, in 2008 there will be an estimated 215,000 new cases of lung cancer diagnosed, and 162,000 deaths caused by this disease in the United States alone. Lung cancer is the number one cause of cancer death throughout the world. "The statistics for global lung cancer deaths are staggering. I am confident that this Phase III trial will establish Lucanix(R) as a viable treatment option for patients with this dreaded disease," said Dr. Habib Fakhrai, president and co-founder of NovaRx.

In Phase II testing, 50 percent of patients entering the trial with stable disease who received Lucanix(TM) following one frontline regimen of chemotherapy lived more than 44 months, compared to less than 10-12 months for such patients under the current standard of care. In addition, patients with advanced disease who received Lucanix(TM) after zero to five prior chemotherapy treatments demonstrated a one-year survival of 61 percent and a two-year survival of 41 percent. Such late-stage patients typically demonstrate one-year survival of less than 30 percent. Lucanix(TM) was shown to produce only insignificant side effects.

"In addition to significantly increased survival," Fakhrai co
'/>"/>

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
5. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
6. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
7. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
8. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
9. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... today announced that David Young, MD, President and,Chief ... Chinese Global,Financial Forum. Dr. Young will present on ... available prior to and following his presentation at ...
... DuPont Chairman and,CEO Charles O. Holliday, Jr., today told ... the world to keep pace with the rapid,growth in ... "Biotechnology is the most powerful tool available to secure ... holds the promise,to deliver the world more, higher quality ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... company, today announced preliminary financial results from,the ... updated its financial,outlook for the full year ... the,release of Boston Scientific Corporation,s (BSC) third ...
Cached Biology Technology:ARIUS to present at Chinese Global Financial Forum 2Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... Virginia Tech,s Wu Feng has built upon a National ... in the Cloud" program, and synergistically complemented it with ... the Air Force on "big computing" for mini-drones and ... Institutes of Health on "big data" for the life ... aspects from each grant, he was able to tell ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... Virtually all babies in the U.S. have their heels ... for genetic testing. These "heel stick" tests identify rare ... more disorders are added to the screening ?many states ... on the rise. In the June issue of Pediatrics, ...
... of their parents may give birds a preference for ... more exactly match those of their parents. Such learned ... traits and strong morphological differences between sexes ?phenomena seen ... reported by Carel ten Cate, Machteld Verzijden and Eric ...
... sub-Saharan Africa, according to the World Health Organization, and ... achieved limited success. But what if a vaccine against ... of Africa ?chancroid ?was relatively easy to develop and ... , That may be the case, according to researchers ...
Cached Biology News:Newborn screening can cause unnecessary parental stress 2Newborn screening can cause unnecessary parental stress 3Zebra finch males prefer females with exaggerated maternal traits 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3
Hepatocyte Differentiation Environment...
High voltage electrophoresis power supply...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... Drummond Scientific has a long and ... microinjection apparatus. Several years ago we ... displacement microdispenser was being modified to ... unit by redesigning the microdispenser to ...
Biology Products: